

PERSONAL INFORMATION

Giuseppe Viglietto



Director, Dipartimento di Medicina Sperimentale e Clinica (DMSC), Magna Graecia University, Catanzaro (I)

+39 0961 369 4281

viglietto@unicz.it

https://scholar.google.it/citations?user=VE0p9POAAAAJ&hl=it

Enterprise	University	EPR
<input type="checkbox"/> Management Level	<input checked="" type="checkbox"/> Full professor	<input type="checkbox"/> Research Director and 1st level Technologist / First Researcher and 2nd level Technologist / Principal Investigator

WORK EXPERIENCE

- From November 2017 Director, Dipartimento di Medicina Sperimentale e Clinica, Magna Graecia University, Catanzaro
- From 2017 to 2020 President, Academic Senate, Magna Graecia University, Catanzaro
- From 2012 to 2017 Scientific Director, Centro Servizi Genomica, Magna Graecia University, Catanzaro
- From December 2004 Full Professor of General Pathology, Director of the Laboratory of Molecular Oncology at Dipartimento di Medicina Sperimentale e Clinica, Magna Graecia University, Catanzaro
- 2001- 2004 Researcher National Research Council of Italy (CNR IEOS), Naples
- 1992-2001 Staff Biologist, IRCCS "Fondazione G Pascale", Naples

EDUCATION AND TRAINING

- 1987 Degree in Biological Sciences, University Federico II, Napoli (110/110L)
- 1991-1994 Residency in Medical Genetics, University La Sapienza, Roma (70/70L)

RESEARCH ACTIVITY

The research activity of prof. Giuseppe Viglietto is documented by the publication of more than 140 manuscripts with 'peer review' in prestigious international journals (EMBOJ, PNAS, Am J Hum Gen, Oncogene, Cancer Res, JCI, Nature Med, Am J Path), seminars as well as from the acquisition of funding for research activities from public and private foundations.

Main scientific contribution of Prof. Viglietto:

- i) cloning of the G6PD gene and molecular characterization of variants (Nucleic Acid Res 1985; EMBOJ 1986; Human Genetics 1989);
- ii) cloning and characterization of the endothelial growth factor PlGF (PNAS, 1991, Oncogene 1994, Lab Inv 1996);
- iii) molecular mechanisms that regulate tumor angiogenesis (Oncogene 1995; Oncogene 1997; Oncogene 1999);
- iv) molecular mechanisms of thyroid carcinogenesis (Oncogene 1995; JCI 1999; Cancer Res 2001; Oncogene 2003; Carcinogenesis 2005; Endocrine-related cancer 2007);
- v) inactivation of CDK inhibitors in cancer (Nature Medicine 2002; Cell Cycle 2004; Am J

Path 2005; Carcinogenesis. 2005; Cell Cycle 2007; Cell Cycle 2012); vi) identification of a new susceptibility gene for sporadic thyroid cancer (Endocrine-related Cancer 2010) or responsible for MEN4 syndrome (European J Endocrinology 2011); vii) identification of a new driver gene in lung cancer (Cell Cycle 2008; Cell Cycle 2009; Am J Path 2010; Am J Path 2011; PlosOne 2012; Oncotarget 2015; J Cancer, 2017; Oncotarget 2017; PlosOne 2017); viii) genetic characterization of ovarian (PlosOne 2013; Transl Oncol. 2021) and colorectal cancers (Oncotarget 2018; J. Exper. Clin Cancer Res 2018; Mol Cancer Res 2018); ix) generation of mouse models of disease (PlosOne 2016; Mol Cancer Ther. 2019); x) role of noncoding RNAs in cancer (RNA Biol. 2017; Cancer Res. 2017; Cell Death Dis. 2018; Noncoding RNA 2020; Cancers 2020).

GRANTS 2012-21 AIRC IG Codice Riferimento: 12969 (2012-2014); MIUR-PRIN prot. 2010W4I4RM_001 (2010-11); MIUR-PON R&C 2007-13, Project PON01_02782; MIUR-PON R&C 2007-2013, Project PON03a_00234; MIUR-PON R&C 2007-2013, Project PON03a_00435; MIUR-PRIN prot. 2017XJ38A4 (2017); MIUR-PRIN prot. 20209KY3Y7_003 (2020).

CLINICAL ACTIVITY

2013-2014 Director of the diagnostic program "Molecular Diagnostic in Oncology" at Fondazione Tommaso Campanella, Catanzaro.

2018-2022 Director of the diagnostic program "Molecular Diagnostic in Oncology" at AOU "Mater Domini", Catanzaro

ADDITIONAL INFORMATION

Publications Total number of publications in peer-review journals: 132
Total Impact Factor (IF): 961.013; (average IF/paper): 7.28
Total number of citations: 8673; H index: 51

1. De Marco C et al., *Genome-wide analysis of copy number alterations led to the characterisation of PDCD10 as oncogene in ovarian cancer*. Transl Oncol. 2021 Mar;14(3):101013.
2. De Marco C et al., *The T197A Knock-in Model of Cdkn1b Gene to Study the Effects of p27 Restoration In Vivo*. Mol Cancer Ther. 2019 Feb;18(2):482-493.
3. Biamonte F et al. *Ferritin heavy subunit enhances apoptosis of non-small cell lung cancer cells through modulation of miR-125b/p53 axis*. Cell Death Dis. 2018 Dec 5;9(12):1174.
4. Mendes Oliveira D et al., *Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene*. J Exp Clin Cancer Res. 2018 Apr 17;37(1):84.
5. Conley et al., *High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients*. RNA Biol. 2017 Mar 4;14(3):305-316.
6. Scrima M et al. *Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients*. J Cancer. 2017 Jan 15;8(2):227-239.

Catanzaro, 28 gennaio 2022

